{"name":"Replimune Group","slug":"replimune","ticker":"REPL","exchange":"NASDAQ","domain":"replimune.com","description":"Replimune Group is a biopharmaceutical company focused on the development of oncolytic immunotherapies for the treatment of cancer. The company's lead product candidate, RP1, is currently in Phase 3 clinical trials for the treatment of melanoma. Replimune has a strong pipeline of oncology products and is well-positioned to capitalize on the growing demand for immunotherapies in oncology.","hq":"Woburn, MA","founded":2017,"employees":"~75","ceo":"Philip Astley-Sparke","sector":"Oncolytic Immunotherapy / Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"1.4B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":189447000,"netIncome":-247297000,"cash":551328000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Replimune Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Replimune reported fourth quarter and full year 2023 financial results, with a net loss of $44.6 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Replimune Announces Collaboration with Merck to Develop Oncolytic Immunotherapies","summary":"Replimune announced a collaboration with Merck to develop oncolytic immunotherapies for the treatment of cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQUjhtbVRlRGlncHlFQWY5UjJlU2tjSVpIbzl6X2tQaWdhbFVxd3hXV05UM0hLVmtjSnRyU3JTZVd1QnVobUZybzhURnkzX29lTkFOS1BYNHd0UnZLRVRxYV9KSzJHN3lidWVUa3dWU2lSS2VzNDctQzVhWWdURWltZWJGUFFNUXVpR2Nkc29VUlRacWZScWpfZnVBNGdCMTAtZDdXRGpTR3I1UjFON3pPTXB4WTJlVGJyUkpB?oc=5","date":"2026-03-30","type":"regulatory","source":"TradingView","summary":"RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease - TradingView","headline":"RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPUnhKTXQ4S2tzbk03c3pDUkdYbVRLMXBObGFSc3ZvQThVX2tUTVo2cDRJd29LUTVuS3FieVNnRnVLakxGUDNPT25tUnFKMWRjU21Ecjh1UXAwSFYtVTdjelVPcDN4bXk5WjdwdkpDOVN6eU9IcGItNTRpMTZWRnZPREpHYlRYRTFZYklBclR4SWtTSHJfTlFseElYLTlna0FwSnBSeVpCbUNMeU41MFBrdTQ0aUt5eFlvNmlyeVI1Q2UyUQ?oc=5","date":"2026-03-04","type":"deal","source":"TradingView","summary":"ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - TradingView","headline":"ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-08","type":"pipeline","source":"simplywall.st","summary":"Is Replimune Group (NASDAQ:REPL) A Risky Investment? - simplywall.st","headline":"Is Replimune Group (NASDAQ:REPL) A Risky Investment?","sentiment":"neutral"},{"date":"2026-02-03","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-02-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQU0RVT2pEak5aZnVRM3Z5UWZaTEIzSXVFX1JEa29rMkRMdl9EN0Y4Ukk4MlM5cWdzaG5qUWJHa1lEQXo3SmFiYlVvbDRNRE9MZmdwWHVVd3VhQ2tZYVpBQzZUeVBHcWk4bC1wY2FXdmY0cGhJNklkX0tVLVBVTWVmMV9vUVd3bURMSzY4SVNISDZBMmQ5?oc=5","date":"2025-12-31","type":"pipeline","source":"Finviz","summary":"Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months - Finviz","headline":"Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-23","type":"regulatory","source":"simplywall.st","summary":"Will FDA Progress Change Replimune Group's (REPL) Position in the Advanced Melanoma Treatment Market? - simplywall.st","headline":"Will FDA Progress Change Replimune Group's (REPL) Position in the Advanced Melanoma Treatment Market?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-21","type":"regulatory","source":"simplywall.st","summary":"Replimune Group (REPL): Valuation Update After FDA Acceptance of RP1 Application Spurs Investor Optimism - simplywall.st","headline":"Replimune Group (REPL): Valuation Update After FDA Acceptance of RP1 Application Spurs Investor Optimism","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxOdlV4eTMwTmhHT29obnR3aUtULTdKSklweUFwbllzOFo1WWxLVTF0X1BDVUVUTUc3N0xZeWF1VDlzUW1nNTVtRzVQRVc5OU1fa2ROOU1BSFp6LVVEV0FuOXNVajJvRUF6ZGVFRzN5M0l0VmJvc3RwVHR1bmVqc3g1MUp3MjI2UVBteVhKdVdxVFJWWWYyWWVfZ3NzSWptNFlzbkJvVHNORjlqMjhDZFZjd19vQS1ZaVg3WjJ0Y2hYNnNPaXc0dEs3OW5WSG5MQ1RQQkdWaEpmaGJxSmtMTl92SkxMeDlnTGVPZzVMQ21pRVNNV0M1QWZnNU92dExJemkwSTRwOG9yVmdhdURIckdYcEZ5ZlBlamVBSkdaQlBKMDBaaVVUUHZveXktTTZuWlpjZ29GU1hsYWx1UEE?oc=5","date":"2025-09-23","type":"pipeline","source":"PR Newswire","summary":"INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL - PR Newswire","headline":"INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOaHhjVUE3VjFMWVloMUFGNGVZalRrbFpNbUN4S0tzN2ExUnFnQ3B4SUJRc3haLW1pZExWMXJZLVZLa2hodFdvbzYwNmdmaHRDbzVPNzZYVVlCR1N0SXdla2s3V1lhRk1zS25zeV8ySXFFUXNCU0VTTklWYlhNTlFQdGNrbHg1ekx3MWFHTElRUHVjRUFqcDhCN3ZzZElYeFZsUlVhQ2JjNU40UQ?oc=5","date":"2025-09-18","type":"regulatory","source":"The Business Journals","summary":"Melanoma drug developer stock crashes after report from FDA meeting - The Business Journals","headline":"Melanoma drug developer stock crashes after report from FDA meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxPMkJwVGtFYXF2YjV2czQyS050dm5WUEFPV2JnNXNGcmQ1QmozdlVoQkdSclFHR1ZJYXRyWUJpSk1WUExRODZqejFHN3c0aE44dXdiODh4MERSN0VWWlFDOUtrX3NzVG5vUkVYM3FOX0xUaFBqQ2JrNlZfZG51dlNZQWRsSU1lRWRVNHJzeVl6OGV2YjI4M0wtV1p6Y2JVQVhNUFJtTnVyUkV6TkNiRGR6bXRka1plVlIwZEQ4OTJZc1FRM21qVHNMLXFIS05mVWxEemhNT2l3MWNoWTgyWmdDbl9zc25ISGJoWWw5QVdicm5fQS1GR3RxOTlYYlY2TFFlbnJxenJKM2I0cWhoUDBvbnV3MWN4OWlNOWZvNFM3NzRIemhRVHpuQWNJdFNQTXJuSmNpay1vSmVZZGlE?oc=5","date":"2025-07-24","type":"pipeline","source":"GlobeNewswire","summary":"REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is - GlobeNewswire","headline":"REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBKZTFXbGl3Y2RBWHVQYUpCc0FONW1pSTFLSUJJS1ZjLThLV0hHcmF2V3Nza01zTFpFdFl4TDRUSm5oTXVVLWg3alRubDdZN0FGVjlNSTV1MWNmUTdMcTA3Qm4tTjRRUGVhb0d0T2ppeUY5UVIzaFdodnJpWm1hUQ?oc=5","date":"2025-07-22","type":"regulatory","source":"Barron's","summary":"Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment - Barron's","headline":"Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment - Barron's","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNNS1TTDdWYXdlM1B3THZNc2MtX1V6NUd0aURnSFdyam1RZDhROV9aMU1OV0FIdVY4X1NOU0k2VXdpMDNPa09OMVRhUGJpRWRIdzJ5N1ZDZ1d6aHMzbXItQ3hhYmhSWWw4NGNrNzJjZVJPdnFjQzljZW5CQ01sOWtYQkZ3RVVJTXQ4U0tkOFhOSlZsdEl5NzNlZlFpQ0RTOFhNVWV5SktJRDQ3bHcyQ3RILXludw?oc=5","date":"2025-04-28","type":"pipeline","source":"Seeking Alpha","summary":"Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma (NASDAQ:REPL) - Seeking Alpha","headline":"Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma (NASDAQ:REPL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE5hdnVDR2dvUVgxTFhYbjNpbGZXTUlMUXNZZ05mVTRHMVJZT2VoNDdXbllfekRyaUg3eU5PWlBlZndBRmJBVWJ6NmprclZnY1Fu?oc=5","date":"2023-12-06","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Amgen Inc."],"therapeuticFocus":["Oncology","Immunotherapy"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":189447000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-247297000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":551328000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}